A citation-based method for searching scientific literature

Maria Valeria Esposito, Giuseppina Minopoli, Luciana Esposito, Valeria D'Argenio, Federica Di Maggio, Emanuele Sasso, Massimiliano D'Aiuto, Nicola Zambrano, Francesco Salvatore. Cancers (Basel) 2019
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
Saira Khalique, Stephen J Pettitt, Ger Kelly, Nina Tunariu, Rachael Natrajan, Susana Banerjee, Christopher J Lord. J Pathol Clin Res 2020
3
33

A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
Lucia Guidugli, Vernon S Pankratz, Namit Singh, James Thompson, Catherine A Erding, Christoph Engel, Rita Schmutzler, Susan Domchek, Katherine Nathanson, Paolo Radice,[...]. Cancer Res 2013
71
33

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Rinske Drost, Peter Bouwman, Sven Rottenberg, Ute Boon, Eva Schut, Sjoerd Klarenbeek, Christiaan Klijn, Ingrid van der Heijden, Hanneke van der Gulden, Ellen Wientjens,[...]. Cancer Cell 2011
160
33

Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
Megan Randall, Kelly Burgess, Lela Buckingham, Lydia Usha. J Natl Compr Canc Netw 2020
4
33

Tubal origin of 'ovarian' low-grade serous carcinoma.
Jie Li, Nisreen Abushahin, Shujie Pang, Li Xiang, Setsuko K Chambers, Oluwole Fadare, Beihua Kong, Wenxin Zheng. Mod Pathol 2011
90
33

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Sarah S Bernards, Kathryn P Pennington, Maria I Harrell, Kathy J Agnew, Rochelle L Garcia, Barbara M Norquist, Elizabeth M Swisher. Gynecol Oncol 2018
29
33

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ielizaveta Gorodetska, Iryna Kozeretska, Anna Dubrovska. J Cancer 2019
49
33

Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1.
José Antonio Rodriguez, Stefan Schüchner, Wendy W Y Au, Megan Fabbro, Beric R Henderson. Oncogene 2004
60
33

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
849
33

Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Rita D Brandão, Klaas Mensaert, Irene López-Perolio, Demis Tserpelis, Markos Xenakis, Vanessa Lattimore, Logan C Walker, Anders Kvist, Ana Vega, Sara Gutiérrez-Enríquez,[...]. Int J Cancer 2019
14
33

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Yifan Wang, John J Krais, Andrea J Bernhardy, Emmanuelle Nicolas, Kathy Q Cai, Maria I Harrell, Hyoung H Kim, Erin George, Elizabeth M Swisher, Fiona Simpkins,[...]. J Clin Invest 2016
48
33

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Joanne Kotsopoulos, Barry Rosen, Isabel Fan, Joel Moody, John R McLaughlin, Harvey Risch, Taymaa May, Ping Sun, Steven A Narod. Gynecol Oncol 2016
55
33

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Barbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, Rochelle Garcia, Jenny Gross, Wataru Sakai, Beth Y Karlan, Toshiyasu Taniguchi, Elizabeth M Swisher. J Clin Oncol 2011
373
33

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Elizabeth M Swisher, Rachel M Gonzalez, Toshiyasu Taniguchi, Rochelle L Garcia, Tom Walsh, Barbara A Goff, Piri Welcsh. Mol Cancer 2009
73
33

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
38
33

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Bing Xia, Qing Sheng, Koji Nakanishi, Akihiro Ohashi, Jianmin Wu, Nicole Christ, Xinggang Liu, Maria Jasin, Fergus J Couch, David M Livingston. Mol Cell 2006
541
33

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
502
33

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Pedro Kringen, Yun Wang, Vanessa Dumeaux, Jahn M Nesland, Gunnar Kristensen, Anne-Lise Borresen-Dale, Anne Dorum. BMC Cancer 2005
15
33

BRCA mutation in high grade epithelial ovarian cancers.
Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn. Gynecol Oncol Rep 2019
15
33

BRCA1-No Matter How You Splice It.
Dan Li, Lisa M Harlan-Williams, Easwari Kumaraswamy, Roy A Jensen. Cancer Res 2019
10
33

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
T Safra, W C Lai, L Borgato, M O Nicoletto, T Berman, E Reich, M Alvear, I Haviv, F M Muggia. Ann Oncol 2013
17
33

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
R Hashizume, M Fukuda, I Maeda, H Nishikawa, D Oyake, Y Yabuki, H Ogata, T Ohta. J Biol Chem 2001
509
33



BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Jing Wang Chiang, Beth Y Karlan, Llana Cass, Rae Lynn Baldwin. Gynecol Oncol 2006
89
33

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
324
33

Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Hyun-Ki Kim, Eun Jin Lee, Young-Jae Lee, Jisun Kim, Yongsub Kim, Kyunggon Kim, Shin-Wha Lee, Suhwan Chang, Young Joo Lee, Jong Won Lee,[...]. J Hum Genet 2020
4
33

Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy.
Beáta Boros-Oláh, Nikoletta Dobos, Lilla Hornyák, Zoltán Szabó, Zsolt Karányi, Gábor Halmos, Jason Roszik, Lóránt Székvölgyi. DNA Repair (Amst) 2019
13
33

Direct DNA binding by Brca1.
T T Paull, D Cortez, B Bowers, S J Elledge, M Gellert. Proc Natl Acad Sci U S A 2001
202
33

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
108
33

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
33

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
747
33

BRCA1 DNA-binding activity is stimulated by BARD1.
Amanda M Simons, Andrew A Horwitz, Lea M Starita, Karen Griffin, R Scott Williams, J N Mark Glover, Jeffrey D Parvin. Cancer Res 2006
41
33

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
I Ruscito, D Dimitrova, I Vasconcelos, K Gellhaus, T Schwachula, F Bellati, R Zeillinger, P Benedetti-Panici, I Vergote, S Mahner,[...]. Eur J Cancer 2014
56
33

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.
Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
109
33

[Circulating tumor DNA assessment for gynaecological cancers management].
Roxane Mari, Éric Lambaudie, Magali Provansal, Renaud Sabatier. Bull Cancer 2019
1
100

RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
Huzefa Dungrawala, Kamakoti P Bhat, Rémy Le Meur, Walter J Chazin, Xia Ding, Shyam K Sharan, Sarah R Wessel, Aditya A Sathe, Runxiang Zhao, David Cortez. Mol Cell 2017
80
33

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly,[...]. Cancer Discov 2013
295
33

PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Sylvie M Noordermeer, Haico van Attikum. Trends Cell Biol 2019
108
33

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
341
33

FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.
Zeina Kais, Beatrice Rondinelli, Amie Holmes, Colin O'Leary, David Kozono, Alan D D'Andrea, Raphael Ceccaldi. Cell Rep 2016
91
33

Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Vladimir M Moiseyenko, Vyacheslav A Chubenko, Fedor V Moiseyenko, Albina S Zhabina, Tatiana V Gorodnova, Yuri I Komarov, Alexey A Bogdanov, Anna P Sokolenko, Evgeny N Imyanitov. Med Oncol 2014
15
33

A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
Lea M Starita, Muhtadi M Islam, Tapahsama Banerjee, Aleksandra I Adamovich, Justin Gullingsrud, Stanley Fields, Jay Shendure, Jeffrey D Parvin. Am J Hum Genet 2018
56
33

Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers.
Angelo Taglialatela, Silvia Alvarez, Giuseppe Leuzzi, Vincenzo Sannino, Lepakshi Ranjha, Jen-Wei Huang, Chioma Madubata, Roopesh Anand, Brynn Levy, Raul Rabadan,[...]. Mol Cell 2017
150
33

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song. J Ovarian Res 2019
19
33

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Kevin K Lin, Maria I Harrell, Amit M Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V Tinker, Elena Helman, Marc R Radke, Carmen Say, Lan-Thanh Vo,[...]. Cancer Discov 2019
108
33

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
Luke Hughes-Davies, David Huntsman, Margarida Ruas, Francois Fuks, Jacqueline Bye, Suet-Feung Chin, Jonathon Milner, Lindsay A Brown, Forrest Hsu, Blake Gilks,[...]. Cell 2003
316
33

A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
Jiyeon Kweon, An-Hee Jang, Ha Rim Shin, Ji-Eun See, Woochang Lee, Jong Won Lee, Suhwan Chang, Kyunggon Kim, Yongsub Kim. Oncogene 2020
21
33

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Yifan Wang, Andrea J Bernhardy, Cristina Cruz, John J Krais, Joseph Nacson, Emmanuelle Nicolas, Suraj Peri, Hanneke van der Gulden, Ingrid van der Heijden, Shane W O'Brien,[...]. Cancer Res 2016
117
33

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
662
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.